摘要
目的探讨康柏西普对年龄相关性黄斑变性患者外周血血管内皮生长因子、眼压及视力变化的影响。方法收集唐山工人医院收治的年龄相关性黄斑变性患者60例,随机分为实验组和对照组,每组各30例,对照组给予雷珠单抗注射液玻璃体腔内注射,实验组给予康柏西普眼用注射液柏玻璃体腔内注射,每月1次,均治疗3个月,治疗结束后,对所有患者的血清VEGF、CRP含量、CMT、CNV水平及荧光素渗漏率、眼压和视力进行检测。结果治疗后,与对照组比较,实验组患者的血清VEGF含量明显较低(P<0.05);实验组患者的血清CRP含量明显较低(P<0.05);实验组患者的CMT、CNV水平及荧光素渗漏率明显较低(P<0.05);实验组患者的视力(log MAR)及IOP水平明显较低(P<0.05)。结论康柏西普眼用注射液能够降低年龄相关性黄斑变性患者外周血VEGF、CRP含量,减少CMT、CNV水平及荧光素渗漏率,降低眼压,改善视力。
Objective To analysis the effect of conbercept ophthalmic injection on peripheral blood vascular endothelial growth factor,intraocular pressure and visual acuity in patients with age related macular degeneration. Methods 60 patients who were diagnosed with age related macular degeneration were collected. All patients were randomly divided into experimental group and control group,30 cases in each group,lucentis intravitreal injection was given into the vitreous cavity in control group,experimental group give conbercept injection into the vitreous cavity,once a month. All patients were treated for 3 months,after the end of treatment,all patients serum VEGF and CRP,CMT,CNV and fluorescence leakage rate,intraocular pressure and visual acuity were detected. Results After treatment,compared with control group,the content of serum VEGF was significantly lower in the experimental group( P < 0. 05). The content of serum CRP was significantly lower in experimental group( P < 0. 05). The CMT,CNV and fluorescence leakage rate were significantly lower in the experimental group( P < 0. 05). The level of IOP and visual acuity( log MAR) were significantly lower in the experimental group( P < 0. 05). Conclusions Conbercept ophthalmic injection can reduce age-related macular degeneration patients week blood VEGF and CRP levels and decrease the CMT,CNV and fluorescence leakage rate,reduce intraocular pressure,visual acuity improvement and have guiding significance for clinic.
出处
《中国生化药物杂志》
CAS
2015年第8期104-106,共3页
Chinese Journal of Biochemical Pharmaceutics
关键词
康柏西普
年龄相关性黄斑变性
血管内皮生长因子
眼压
视力
conbercept ophthalmic injection
age-related macular degeneration
vascular endothelial growth factor
intraocular pressure
visual acuity